Use of Cistanche tubulosa extract in preparation of a medicament for relieving dry eye symptoms. Said symptoms include ocular burning, itching, stinging, excess watering, foreign body sensation, pain, redness, photophobia and blurred vision.
A61K 36/64 - Orobanchaceae (famille de l'orobranche)
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
Use of Cistanche tubulosa extract in preparation of a medicament for relieving dry eye symptoms. Said symptoms includ ocular burning, itching, stinging, excess watering, foreign body sensation, pain, redness, photophobia and blurred vision.
A composition, comprising a first component --- Cistanche tubulosa extract and a second component --- an oxidized coenzyme (Q10) and/or a reduced coenzyme (QH). The weight ratio of the two components is: first component:second component=0.67:1 to 10:1. The composition is a pharmaceutical composition, a food composition, a cosmetic composition, a health care product composition, or a feed composition. The pharmaceutical composition may be used for treating or preventing chronic fatigue syndrome. The food composition, cosmetic composition, health care product composition or feed composition may be used in at least one of the following situations: improving endurance or strength in exercising, enhancing or restoring physical strength, eliminating fatigue, preventing myocardial weakness, and improving cardiac weakness or cardiac performance.
An application of a Poria extract and/or active ingredients thereof in the preparation of a composition. The composition is used for the modification, prevention and/or treatment of lung injury and/or lung injury-related diseases. Moreover, the active ingredients are selected from the group comprising tumulosic acid, dehydrotumulosic acid, dehydrotrametenolic acid, poricoic acid A, and combinations thereof.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
5.
USE OF PORIA EXTRACT AND ACTIVE INGREDIENT THEREOF IN SKIN CARE AND/OR PROMOTING WOUND HEALING
Provided are a use of Poria extract, dehydropachymic acid (DPA), pachymic acid (PA), dehydrotumulosic acid (DTA), tumulosic acid (TA), polyporenic acid C (PAC), 3-epi-dehydrotumulosic acid (EDTA), dehydrotrametenolic acid (DTTA), trametenolic acid (TTA), dehydroeburicoic acid (DEA), eburicoic acid (EA), poricoic acid A (PAA), and/or poricoic acid B (PAB) in preparing a formulation, said formulation being used for skin care and/or promoting wound healing.
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61Q 19/00 - Préparations pour les soins de la peau
A61Q 19/08 - Préparations contre le vieillissement
6.
PORIA COCOS FERMENTATION PRODUCT AND PREPARATION METHOD THEREFOR
A Poria cocos fermentation product. On the basis of the total weight of the Poria cocos fermentation product, the total amount of the following compounds (1) to (12) is no less than 0.15% by weight: (1) pachymic acid (PA), (2) dehydropachymic acid (DPA), (3) tumulosic acid (TA), (4) dehydrotumulosic acid (DTA), (5) polyporenic acid C (PAC), (6) 3-epi-dehydrotumulosic acid (EDTA), (7) dehydrotrametenolic acid (DTTA), (8) trametenolic acid (TTA), (9) poricoic acid A (PAA), (10) dehydroeburicoic acid (DEA), (11) poricoic acid B (PAB), and (12) eburicoic acid (EA). The Poria cocos fermentation product is prepared by using the following method: (a) placing a solid substrate in a fermentation vessel; (b) inoculating a Poria cocos strain on the solid substrate; (c) culturing by fermentation, wherein the solid substrate contains rhizomatous crops, melon crops or a combination thereof.
An application using at least a poricoic acid A and a poricoic acid B for preparing a pharmaceutical product or foodstuff, wherein the pharmaceutical product or foodstuff is used for blood sugar modulation. At least one of the poricoic acid A and poricoic acid B can be used in the form of a plant extract. A total content of the poricoic acid A and poricoic acid B in the plant extract is at least 30% of the total weight of the plant extract. The foodstuff can be used as a health food, dietary supplement food, or specialized nutritional food.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/194 - Acides carboxyliques, p. ex. acide valproïque ayant plusieurs groupes carboxyle, p. ex. acides succinique, maléique ou phtalique
Uses of a poria cocos extract, a tumulosic acid and/or a pharmaceutically acceptable salt of the tumulosic acid in the preparation of a drug or food, and the drug or the food is used for protecting muscles. The drug is especially used for resisting against muscle cell damages and promoting the regeneration and recovery of muscles, so as to adjust, treat and/or delay muscle atrophies, and especially muscle atrophies caused by aging, diseases and/or cachexia. The food is a health food, a nutrient supplementary food or a special nutritional food.
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
9.
USE OF CISTANCHE TUBULOSA EXTRACT AND ISOACTEOSIDE IN PROTECTION OF MUSCLES
Disclosed is a use of a Cistanche tubulosa extract, isoacteoside and/or a pharmaceutically acceptable salt of isoacteoside for the preparation of a drug or a food, wherein the drug or food is used to protect muscles. The drug is especially used for anti-muscle cell injuries, so as to regulate, treat and/or delay muscle loss, in particular due to aging, diseases and/or cachexia. The food is a health food, nutrition-replenishing food or special nutritional food.
Cistanche tubulosa extract, isoacteoside and/or a pharmaceutical acceptable salt of isoacteoside in the manufacture of a medicament or a food product for protecting muscles, wherein the medicament is particularly used for protecting muscle cells against injury to regulate, treat and/or delay muscle loss, and especially for the muscle loss caused by aging, diseases, and/or cochexia. The food product is a health food, a nutritional supplement food, or a special nutrition food.
Disclosed is a use of cistanche tubulosa extract in the preparation of drugs or foods for protecting ocular cells. The extract also can be prepared into drugs or foods for preventing ocular diseases or delaying the progression of ocular diseases.
A method for providing poria cocos extract of K2 with an increment. The method comprises the following steps:(a) mixing poria cocos with a solvent to provide a first mixture; (b) alkalifying the first mixture to obtain a second mixture; (c) acidizing the second mixture to obtain a third mixture; (d) alkalifying the third mixture to obtain a fourth mixture with a pH value greater than 7; and (e) neutralizing the fourth mixture, wherein K2 is at least one of tumulosic acid, dehydrotumulosic acid, polyporenic acid C, and 3-epi-dehydrotumulosic acid.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
An isoacteoside derivative and preparation method and use thereof; the isoacteoside derivative has a structure of formula (I): R1 and R2 are independently selected from hydrogen, halogen, hydroxyl and alkoxy oxyl; R3 and R4 are independently selected from hydroxyl, alkoxy oxyl and acyloxy; R5 is independently selected from hydroxyl or acyloxy. Drugs comprising the isoacteoside derivative have uses of treating or preventing amyloid peptide related diseases and preventing eye lesions and the like.
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Disclosed is use of an active ingredient in the preparation of a medicament, wherein the medicament is used to increase the expression quantity of SIRT1 mRNA and/or reduce the expression quantity of SOCS3 mRNA, and it can especially it can be used to regulate blood sugar, and the active ingredient is selected from the following groups: compounds of formula (I), pharmaceutically acceptable salts of compounds of formula (I), and combinations of the foregoing. In formula (I), X is H or C1-C3 alkyl, one of Y and Z is formula (I') and the other is H, OH, or formula (I''), wherein when Y is formula (I'), Z is formula (I"), and R1 to R13 are independently H or OH, and wherein R1 and R3 are not H at the same time, and R8 and R9 are not H at the same time.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A61K 36/64 - Orobanchaceae (famille de l'orobranche)
A medical composition containing acteoside and isoacteoside is capable of inhibiting the generation, accumulation or concentration of amyloid β peptide, and can be therefore used to prevent or treat amyloid β peptide related diseases or conditions. The ratio of the weight of the isoacteoside to that of the acteoside ranges from 4:1 to 1:4.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
16.
USE OF ISOACTEOSIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
Isoacteoside or a pharmaceutically acceptable salt thereof which is used as an inhibitor of production, accumulation or aggregation of amyloid β peptide has effect on preventing or treating diseases or symptoms associated with amyloid β peptide.
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A pharmaceutical composition for treating diabetes comprising lanostanes as effective constituents is provided by the present invention. The suitable source of the lanostanes is the extracts from Poria which comprise 1-60% (by weight) lanostanes without secolanostanes substantially. The extracts are extracted from the metabolite, fermented product or mycelium of Polyporaceae plant Poria (Poria cocos (Schw) Wolf).
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A pharmaceutical composition for treating or preventing angina or myocardial infarction is disclosed in the present invention. Tea extracts (catechins) are used in combination with antianginal agents to treat angina or myocardial infarction induced by myocardial ischemia.
A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
A61K 31/21 - Esters, p. ex. nitroglycérine, sélénocyanates
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/616 - Acide salicyliqueSes dérivés ayant le groupe hydroxyle en position 2 estérifié, p. ex. acide salicylsulfurique par des acides carboxyliques, p. ex. acide acétylsalicylique
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
19.
USE OF LANOSTANES AND EXTRACTS FROM PORIA COCOS FOR TREATING CACHEXIA
A pharmaceutical composition for treating cachexia, especially cachexia induced by cancer, comprising lanostanes as effective constituents. The suitable source of the lanostanes is the extracts from Poria cocos which comprise 1-60% (by weight) lanostanes without secolanostanes substantially. The extracts are extracted from the metabolite, fermented product or mycelium of Poria cocos (Schw) Wolf (Polyporaceae plant).
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
The present invention provides the use of lanostanes represented by formula (I) or pharmaceutically acceptable salts thereof in the manufacture of medicaments for treating diseases caused by immune disturbance which including allergic diseases such as allergic rhinitis, anaphylactic conjunctivitis, allergic asthma, atopic dermatitis, esophagus supersensitivity, atopic eczema and rheumatoid arthritis. In formula (I), R1 is H or CH3; R2 is OCOCH3, =O or OH; R3 is H or OH; R4 is -C(=CH2)-C(CH3)2Ra, wherein Ra is H or OH, or -CH=C(CH3)-Rb, wherein Rb is CH3 or CH2OH; R5 is H or OH; and R6 is CH3 or CH2OH.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
The invention provides a new use of lanostanes of formula (I) or the pharmaceutically acceptable salts thereof for enhancing absorption of nutrients. In the formula above-mentioned, R1 is H or CH3; R2 is OCOCH3, =O or OH; R3 is H or OH; R4 is -C(=CH2)-C(CH3)2Ra or -CH=C(CH3)-Rb; wherein Ra is H or OH, Rb is CH3 or CH2OH; R5 is H or OH; and R6 is CH3 or CH2OH.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A neuroblast proliferation promoter comprising phenylethanol glycoside compounds or the extract of Cistanche, which can promote the proliferation of neuroblast and the outgrowth of neurite of neuroblast at the condition of neuroblast having no disorder. The neuroblast proliferation promoter can be used to prepare medicine, the external formulation for skin, the food for drinking and the feed for mammal.
The present invention is related to a novel use of a lanostane having the following formula (I) or a pharmaceutically acceptable salt thereof in enhancing uptake of nutrients: (see formula I)
wherein R1 is either H or CH3; R2 is OCOCH3, =O or OH; R3 is H or OH; R4 is -C(=CH2)-C(CH3)2R a or -CH=C(CH3)-R b, in which R a is H or OH, and R b is CH3
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
Isoacteoside or a pharmaceutically acceptable salt thereof is used as an inhibitor of production, accumulation or aggregation of amyloid .beta. peptide has effect on preventing or treating diseases or symptoms associated with amyloid .beta. peptide.
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A pharmaceutical composition containing isoacteoside to the acteoside is provided, which is able to inhibit formation, accumulation or aggregation of amyloid .beta. peptides, and is thus useful in preventing or treating amyloid beta peptide-associated diseases or conditions, wherein a weight ratio of the isoacteoside to the acteoside is 4:1 to 1:4.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
27.
K2 COMPOSITION, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
A method for providing poria cocos extract of K2 with an increment. The method comprises the following steps: (a) mixing poria cocos with a solvent to provide a first mixture; (b) alkalifying the first mixture to obtain a second mixture; (c) acidizing the second mixture to obtain a third mixture, (d) alkalifying the third mixture to obtain a fourth mixture with a pH value greater than 7; and (e) neutralizing the fourth mixture, wherein K2 is at least one of tumulosic acid, dehydrotumulosic acid, polyporenic acid C, and 3-epi-dehydrotumulosic acid.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
Disclosed is a use of a Cistanche tubulosa extract, isoacteoside and/or a pharmaceutically acceptable salt of isoacteoside for the preparation of a drug or a food, wherein the drug or food is used to protect muscles. The drug is especially used for anti-muscle cell injuries, so as to regulate, treat and/or delay muscle loss, in particular due to aging, diseases and/or cachexia. The food is a health food, nutrition-replenishing food or special nutritional food.
Uses of a poria cocos extract, a tumulosic acid and/or a pharmaceutically acceptable salt of the tumulosic acid in the preparation of a drug or food, and the drug or the food is used for protecting muscles. The drug is especially used for resisting against muscle cell damages and promoting the regeneration and recovery of muscles, so as to adjust, treat and/or delay muscle atrophies, and especially muscle atrophies caused by aging, diseases and/or cachexia. The food is a health food, a nutrient supplementary food or a special nutritional food.
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
30.
PHARMACEUTICAL COMPOSITION AND EXTRACT OF PORIA FOR TREATING A DISEASE INDUCED FROM IMMUNE DISORDER
The present invention is related to a novel use of a lanostane having the following formula (I) or a pharmaceutically acceptable salt thereof in treating a disease induced from immune disorder:
wherein R1 is either H or CH3; R2 is OCOCH3, =0 or OH; R3 is H or OH; R4 is -C(=CH2)-C(CH3)2R a, in which R a is H or OH, or -CH=C(CH3)-R b, in which R b is CH3 or CH2OH; R5 is H or OH; and R6 is CH3 or CH2OH.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
brevets
